MDAI vs GMED vs AEYE vs LNSR vs ISRG

For growth investors, Spectral AI, Inc.

(MDAI) is the stronger pick with 63. 8% revenue growth year-over-year, versus 9. 2% for LENSAR, Inc. (LNSR). Globus Medical, Inc. (GMED) offers the better valuation at 21. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Globus Medical, Inc. (GMED) a "Buy" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Globus Medical, Inc.

(GMED) is the cheapest at 21. 7x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Globus Medical, Inc. is actually cheaper at 19. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Globus Medical, Inc. wins at 0. 61x versus Intuitive Surgical, Inc. 's 2. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -76. 9% for Spectral AI, Inc. (MDAI). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus MDAI's -76. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), LENSAR, Inc.

(LNSR) is the lower-risk stock at 0. 52β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 337% more volatile than LNSR relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 15% for AudioEye, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Spectral AI, Inc.

(MDAI) is pulling ahead at 63. 8% versus 9. 2% for LENSAR, Inc. (LNSR). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to -5. 1% for LENSAR, Inc.. Over a 3-year CAGR, GMED leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -58. 7% for LENSAR, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -42. 1% for LNSR. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Globus Medical, Inc. (GMED) is the more undervalued stock at a PEG of 0. 61x versus Intuitive Surgical, Inc. 's 2. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Globus Medical, Inc. (GMED) trades at 19. 0x forward P/E versus 1341. 0x for LENSAR, Inc. — 1322. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ISRG: 37. 3% to $622. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, LENSAR, Inc.

(LNSR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 52)). AudioEye, Inc. (AEYE) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LNSR: -41. 9%, AEYE: +102. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MDAI (Healthcare) and GMED (Healthcare) and AEYE (Technology) and LNSR (Healthcare) and ISRG (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MDAI is a small-cap high-growth stock; GMED is a mid-cap high-growth stock; AEYE is a small-cap quality compounder stock; LNSR is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.